Skip to main content
P

Pathbiotech

This company utilizes a proprietary AI platform, PATHTM, to integrate big 'omics' and single-cell data for discovering novel druggable targets. The platform predicts precision therapeutics and refines them through an iterative framework with biological models. PATH Biotech is currently advancing small-molecule drugs for neurodegenerative diseases, cancer, and autoimmune conditions toward clinical trials.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

  • This company utilizes a proprietary AI platform, PATHTM, to integrate big 'omics' and single-cell data for discovering novel druggable targets. The platform predicts precision therapeutics and refines them through an iterative framework with biological models. PATH Biotech is currently advancing small-molecule drugs for neurodegenerative diseases, cancer, and autoimmune conditions toward clinical trials.
This profile is AI-generated and may contain inaccuracies.